^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Sortilin inhibitor

    Related drugs:
    1m
    89Zr/177Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics. (PubMed, J Med Chem)
    Moreover, 11.1 MBq [177Lu]Lu-DOTA-latozinemab significantly suppressed tumor growth via induction of DNA damage, as evidenced by increased 53BP1 foci. These findings establish the first SORT1-directed theranostic radiopharmaceutical pair, exhibiting high specificity and therapeutic potency for managing SORT1-positive cancers.
    Journal
    |
    SORT1 (Sortilin 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    2ms
    223646: GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. (2025-521107-42-00)
    P1/2, N=143, Recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    3ms
    Continuation Study for Latozinemab (clinicaltrials.gov)
    P3, N=17, Terminated, Alector Inc. | N=35 --> 17 | Trial completion date: Nov 2027 --> Jan 2026 | Enrolling by invitation --> Terminated | Trial primary completion date: Jul 2027 --> Sep 2025; The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3ms
    A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) (clinicaltrials.gov)
    P3, N=119, Terminated, Alector Inc. | Trial completion date: Aug 2027 --> Jan 2026 | Active, not recruiting --> Terminated; The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)
    Trial completion date • Trial termination
    6ms
    Open-label Extension Study in Participants With Early Alzheimer's Disease (clinicaltrials.gov)
    P2, N=297, Recruiting, GlaxoSmithKline | N=226 --> 297 | Not yet recruiting --> Recruiting
    Enrollment open • Enrollment change
    7ms
    PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=80, Recruiting, ProteinQure Inc.
    New P1 trial
    8ms
    Open-label Extension Study in Participants With Early Alzheimer's Disease (clinicaltrials.gov)
    P2, N=226, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    12ms
    TH1902-CTR-0001: TH1902 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Theratechnologies | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    sudocetaxel zendusortide (TH 1902)
    12ms
    PROGRESS-AD: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (clinicaltrials.gov)
    P2, N=359, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting
    Enrollment closed
    1year
    PROGRESS-AD: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (clinicaltrials.gov)
    P2, N=282, Recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Nov 2026
    Trial completion date
    1year
    A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) (clinicaltrials.gov)
    P2, N=33, Completed, Alector Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jun 2024 | Trial primary completion date: Jan 2026 --> Jun 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    GRN (Granulin Precursor)
    over1year
    An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. (PubMed, Front Immunol)
    Our results introduce A3-PGRNC15* as a promising new agent with therapeutic potential for the treatment of frontotemporal dementia. Furthermore, the work highlights means to increase binding affinity through synergistic contribution from two orthogonal polypeptide units.
    Journal
    |
    SORT1 (Sortilin 1) • GRN (Granulin Precursor)